United StatesAn analysis suggests that a provision in the One Big Beautiful Bill Act, which grants exemptions from Medicare price negotiations for certain orphan drugs, may not be justified. The provision, part of the Orphan Cures Act, allows drugs with multiple orphan designations to avoid price negotiation under the Inflation Reduction Act. Critics argue these exemptions could limit competition and keep prices high for patients. The analysis raises concerns about whether the expanded exemptions are necessary to incentivize drug development.
Bias read (Center): The article presents an analysis questioning the justification for expanded orphan drug exemptions but does not take a clear ideological stance. It reports on the controversy without overtly favoring either side, maintaining a balanced tone. The framing focuses on the potential impact on drug prices
